Statement: The longest Time to Disease Progression the primary trial was over 11 months  in the Docetaxel Plus Capecitabine group.
Primary_evidence: Outcome Measurement:    Time to Disease Progression (Initial Treatment)   Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment.   Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months) Results 1:    Arm/Group Title: Gemcitabine Plus Docetaxel   Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous, days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous, day 1 every 21 days.   Treatment continues until progression of disease at which time crossover treatment begins.   Overall Number of Participants Analyzed: 239   Median (95% Confidence Interval)   Unit of Measure: months  9.28        (7.73 to 10.79) Results 2:    Arm/Group Title: Docetaxel Plus Capecitabine   Arm/Group Description: docetaxel 75 mg/m2, intravenous, day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a day, days 1-14 every 21 days. Treatment continues until progression of disease, at which time crossover treatment begins.   Overall Number of Participants Analyzed: 236   Median (95% Confidence Interval)   Unit of Measure: months  8.88        (7.37 to 11.05)